Validation pour Ingenuity232

vers la météo de la validation par utilisateur

Ingenuity232

precedent - 0 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56 57 58 59 60 61 62 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 78 79 80 81 82 83 84 85 86 87 88 89 90 91 92 93 94 95 96 97 98 99 - suivant

Phrase 29 - PMID ?

In HASMC cells , GW9662 decreases expression of SP NODE mRNA that is increased by ciglitazone .

Non annotée
Je ne sais pas
Je n'ai pas trouvé d'analyse satisfaisante

Commentaires :

Analyse 0

                                        +-------COMP:N-N(of)-------+                                    
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                                    
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 1

                                        +--------------SUBJ:V_PASS-N--------------+                     
                                        +-------COMP:N-N(of)-------+              |                     
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 2

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                            |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 3

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +--------------SUBJ:V_PASS-N--------------+             |       
                             |          +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 4

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                            |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 5

                                        +--------------SUBJ:V_PASS-N--------------+                     
                                        +-------COMP:N-N(of)-------+              |                     
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,expression)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 6

                                        +--------------SUBJ:V_PASS-N--------------+                     
                                        +-------COMP:N-N(of)-------+              |                     
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 7

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +--------------SUBJ:V_PASS-N--------------+             |       
                             |          +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,expression)

Analyse 8

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +--------------SUBJ:V_PASS-N--------------+             |       
                             |          +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 9

                                                            +-------OBJ:V-N-------+                     
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 10

            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+-------OBJ:V-N-------+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 11

                                        +-------COMP:N-N(of)-------+                                    
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+--------COMP:N-N(by)--------+       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(by) (mRNA,ciglitazone)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 12

                                                    +-----------OBJ:V-N-----------+                     
            +--COMP:V-N(In)--+                      |              +---SUBJ:V-N---+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 13

            +--COMP:V-N(In)--+                      +-----------OBJ:V-N-----------+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 14

                                        +-----------------OBJ:V-N-----------------+                     
            +--COMP:V-N(In)--+          |                          +---SUBJ:V-N---+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 15

            +--COMP:V-N(In)--+          +-----------------OBJ:V-N-----------------+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 16

                                        +-----------------OBJ:V-N-----------------+                     
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 17

                                        +-----------------OBJ:V-N-----------------+                     
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+                     |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)
COMP:V-N(by) (increase,ciglitazone)

Analyse 18

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |                              +-------OBJ:V-N-------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 19

                             +---------------------------COMP:V-N(by)---------------------------+       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+-------OBJ:V-N-------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 20

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |                      +-----------OBJ:V-N-----------+             |       
            +--COMP:V-N(In)--+                      |              +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 21

                             +---------------------------COMP:V-N(by)---------------------------+       
            +--COMP:V-N(In)--+                      +-----------OBJ:V-N-----------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 22

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +--------------SUBJ:V_PASS-N--------------+             |       
                                        +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,expression)

Analyse 23

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +--------------SUBJ:V_PASS-N--------------+             |       
                                        +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 24

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +--------------SUBJ:V_PASS-N--------------+             |       
                                        +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 25

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          |                          +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 26

                             +---------------------------COMP:V-N(by)---------------------------+       
            +--COMP:V-N(In)--+          +-----------------OBJ:V-N-----------------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 27

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 28

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+                     |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 29

                                        +-------COMP:N-N(of)-------+                                    
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,mRNA)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 30

                                        +-------COMP:N-N(of)-------+                                    
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                                    
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 31

                                        +----------------------COMP:N-N(by)---------------------+       
                                        |                   +-------OBJ:V-N-------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 32

                                        +----------------------COMP:N-N(by)---------------------+       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+-------OBJ:V-N-------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 33

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 34

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                            |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 35

                                        +----------------------COMP:N-N(by)---------------------+       
                                        |           +-----------OBJ:V-N-----------+             |       
            +--COMP:V-N(In)--+          |           |              +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 36

                                        +----------------------COMP:N-N(by)---------------------+       
            +--COMP:V-N(In)--+          |           +-----------OBJ:V-N-----------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 37

            +-----------------------------COMP:V-N(In)----------------------------+                     
            |                           +-----------------SUBJ:V-N----------------+                     
            |                           +-------COMP:N-N(of)-------+              |                     
            |        +----MOD_ATT:N-N---+           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        |       +MOD_ATT:N-+           |       +MOD_AT+SUBJ:V-N+     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
MOD_ATT:N-N (expression,GW9662)
MOD_ATT:N-N (expression,decrease)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
COMP:V-N(In) (increase,cell)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,ciglitazone)

Analyse 38

            +-----------------------------COMP:V-N(In)----------------------------+                     
            |                           +-----------------SUBJ:V-N----------------+                     
            |                           +-------COMP:N-N(of)-------+              |                     
            |        +----MOD_ATT:N-N---+           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        |       +MOD_ATT:N-+           |       +MOD_AT+              +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
MOD_ATT:N-N (expression,GW9662)
MOD_ATT:N-N (expression,decrease)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,cell)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,ciglitazone)

Analyse 39

                                        +--------------SUBJ:V_PASS-N--------------+                     
                                        +--------------SUBJ:V-N-------------+     |                     
                                        +-------COMP:N-N(of)-------+        |     |                     
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+        |     |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+        |     +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
SUBJ:V_PASS-N (increase,expression)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 40

                                        +--------------SUBJ:V_PASS-N--------------+                     
                                        +-------COMP:N-N(of)-------+              |                     
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              +COMP:V_PASS-N+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)
COMP:V_PASS-N(by) (increase,ciglitazone)

Analyse 41

            +-----------------------------COMP:V-N(In)----------------------------+                     
            |                           +-----------------SUBJ:V-N----------------+                     
            |                           +--------------SUBJ:V-N-------------+     |                     
            |                           +-------COMP:N-N(of)-------+        |     |                     
            |        +----MOD_ATT:N-N---+           +-MOD_ATT:N-ADJ+        |     |                     
      +MOD_A+        |       +MOD_ATT:N-+           |       +MOD_AT+        |     +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
MOD_ATT:N-N (expression,GW9662)
MOD_ATT:N-N (expression,decrease)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
COMP:V-N(In) (increase,cell)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,ciglitazone)

Analyse 42

            +-----------------------------COMP:V-N(In)----------------------------+                     
            |                           +-----------------SUBJ:V-N----------------+                     
            |                           +-------COMP:N-N(of)-------+              |                     
            |        +----MOD_ATT:N-N---+           +-MOD_ATT:N-ADJ+              |                     
      +MOD_A+        |       +MOD_ATT:N-+           |       +MOD_AT+              +-COMP:V-N(by)+       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
MOD_ATT:N-N (expression,GW9662)
MOD_ATT:N-N (expression,decrease)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:V-N(In) (increase,cell)
SUBJ:V-N (increase,expression)
COMP:V-N(by) (increase,ciglitazone)

Analyse 43

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +--------------SUBJ:V_PASS-N--------------+             |       
                             |          +--------------SUBJ:V-N-------------+     |             |       
                             |          +-------COMP:N-N(of)-------+        |     |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+        |     |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+        |     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
SUBJ:V_PASS-N (increase,expression)

Analyse 44

                             +---------------------------COMP:V-N(by)---------------------------+       
                             |          +--------------SUBJ:V_PASS-N--------------+             |       
                             |          +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:V-N(by) (decrease,ciglitazone)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 45

                                        +-------COMP:N-N(of)-------+--------COMP:N-N(by)--------+       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(by) (mRNA,ciglitazone)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 46

                                        +-------COMP:N-N(of)-------+                                    
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+--------COMP:N-N(by)--------+       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
COMP:N-N(by) (mRNA,ciglitazone)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 47

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+-SUBJ:V_PASS-N+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 48

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-------COMP:N-N(of)-------+                            |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+                            |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+-SUBJ:V_PASS-N+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,mRNA)

Analyse 49

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +--------------SUBJ:V_PASS-N--------------+             |       
                                        +--------------SUBJ:V-N-------------+     |             |       
                                        +-------COMP:N-N(of)-------+        |     |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+        |     |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+        |     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,expression)
SUBJ:V_PASS-N (increase,expression)

Analyse 50

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +--------------SUBJ:V_PASS-N--------------+             |       
                                        +-------COMP:N-N(of)-------+              |             |       
            +--COMP:V-N(In)--+          |           +-MOD_ATT:N-ADJ+              |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           |       +MOD_AT+              |             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,mRNA)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__SP__)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V_PASS-N (increase,expression)

Analyse 51

                                                            +------------COMP:N-N(by)-----------+       
                                                            +-------OBJ:V-N-------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
COMP:N-N(by) (__NODE__,ciglitazone)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 52

                                                            +------------COMP:N-N(by)-----------+       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+-------OBJ:V-N-------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
MOD_ATT:N-ADJ (__NODE__,__SP__)
COMP:N-N(by) (__NODE__,ciglitazone)
OBJ:V-N (increase,__NODE__)
SUBJ:V-N (increase,mRNA)

Analyse 53

                                                    +----------------COMP:N-N(by)---------------+       
                                                    +-----------OBJ:V-N-----------+             |       
            +--COMP:V-N(In)--+                      |              +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (__SP__,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 54

                                                    +----------------COMP:N-N(by)---------------+       
            +--COMP:V-N(In)--+                      +-----------OBJ:V-N-----------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (__SP__,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,__SP__)
SUBJ:V-N (increase,mRNA)

Analyse 55

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          |                          +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 56

                                        +----------------------COMP:N-N(by)---------------------+       
            +--COMP:V-N(In)--+          +-----------------OBJ:V-N-----------------+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+COMP:N-N(of+       +MOD_AT+---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__SP__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (mRNA,__NODE__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 57

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+      +---SUBJ:V-N---+             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +SUBJ:V-N+     |             |       
      |     |        |       |          |           |       |      |        |     |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (__NODE__,__SP__)
SUBJ:V-N (be,mRNA)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)

Analyse 58

                                        +----------------------COMP:N-N(by)---------------------+       
                                        +-----------------OBJ:V-N-----------------+             |       
            +--COMP:V-N(In)--+          +----COMP:N-N(of)---+                     |             |       
      +MOD_A+        +SUBJ:V-+--OBJ:V-N-+           +MOD_ATT+      +---SUBJ:V-N---+             |       
      |     |        |       |          |           |       |      |              |             |       
 In HASMC cells , GW9662 decreases expression of __SP__ __NODE__ mRNA that is increased by ciglitazone .
MOD_ATT:N-N (cell,HASMC)
COMP:V-N(In) (decrease,cell)
SUBJ:V-N (decrease,GW9662)
OBJ:V-N (decrease,expression)
COMP:N-N(of) (expression,__NODE__)
COMP:N-N(by) (expression,ciglitazone)
MOD_ATT:N-ADJ (__NODE__,__SP__)
OBJ:V-N (increase,expression)
SUBJ:V-N (increase,mRNA)